Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7851624 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7851624 | EXPERIMENTAL | Participants will receive RO7851624 in a dose escalation stage followed by a dose expansion stage. |
| Name | Type | Description |
|---|---|---|
| RO7851624 | DRUG | Participants will receive RO7851624 as per the schedule described in the protocol. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy of at least 12 weeks. * Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria. * Measurable disease. Exclusion Criteria: * Treatment with any chemotherap...
Top 20 of 25 competitors
RO7851624 is an investigational small molecule being developed for the treatment of relapsed/refractory multiple myeloma (RRMM). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
RO7851624 is being developed by Roche Holding AG, a biopharmaceutical company traded on the OTC market under the ticker symbol RHHBY. The drug is currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.
RO7851624 is in Phase 1 clinical development. It is an investigational drug being studied in a single active trial for relapsed/refractory multiple myeloma. The drug has not been approved and remains in early-stage clinical testing.
RO7851624 is being evaluated in a Phase 1 clinical trial with the identifier NCT07558915, titled 'A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM).' The trial is currently recruiting participants in Australia and aims to enroll 160 patients aged 18 years and older.
RO7851624 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for relapsed/refractory multiple myeloma. The drug is being studied in an ongoing clinical trial and has not yet received regulatory approval.